Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings: Forget The Short Term Noise
Lantheus remains fundamentally strong despite recent stock drops, with long-term prospects intact for PYLARIFY and Alzheimer's diagnostics. PYLARIFY dominates revenue and has a significant growth runway if adoption expands, representing a multi-billion dollar opportunity by 2030. Alzheimer's market entry is a bullish catalyst, with two promising imaging agents and a large, untapped addressable market.
Lantheus Seems Worth The (Very Real) Risks
Lantheus Holdings offers a compelling bull case with PYLARIFY and DEFINITY driving valuation and strong growth prospects. A headline multiple of 12x 2025 earnings obscures real risks around PYLARIFY revenue, pricing, and rising competition. PYLARIFY's dominance in prostate cancer imaging has fueled massive stock gains, but new competitors like Telix and Blue Earth threaten its market share.
Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy
Lantheus shares fell 25% post-Q1 2025 report due to disappointing EPS guidance and not meet analysts' expectations. EPS reduction was driven by flat PYLARIFY sales and changes in Medicare coverage, impacting profitability and gross margins. Strategic transformation includes divesting the low-margin SPECT segment and acquiring LMI and Evergreen to expand into lucrative Alzheimer's and cancer diagnostics markets.
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams.
Lantheus' Pylarify Hit $1B in 2024 Sales
Lantheus Holdings (LNTH -1.07%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions.
Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital Markets David Turkaly - Citizens JMP Operator Good morning.
Lantheus (LNTH): A 10x Opportunity in Radiopharmaceuticals
Explore the exciting world of Lantheus Holdings (LNTH 1.39%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day.
Lantheus Holdings: Powerhouse Potential In 2025
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability.
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%).
Lantheus Holdings: A Growing Business With Dominant Market Share
Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent execution, particularly with PYLARIFY, which is on track to exceed $1 billion in sales by Q4 2024. The company is financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow, positioning it well for acquisitions.
Why Lantheus Holdings Stock Won Big on Wednesday
Why Lantheus Holdings Stock Won Big on Wednesday
